Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement

IF 2.3 3区医学 Q2 HEMATOLOGY

European Journal of Haematology Pub Date : 2024-10-12 DOI:10.1111/ejh.14325

R. Liévin, B. Burroni, E. Balducci, P. Palmic, J. Decroocq, B. Deau-Fischer, P. Franchi, M. Vignon, J. Zerbit, A. S. Cottereau, A. Touzart, P. Villarese, S. Kaltenbach, L. Lhermitte, V. Asnafi, D. Bouscary, L. Willems

{"title":"Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement","authors":"R. Liévin, B. Burroni, E. Balducci, P. Palmic, J. Decroocq, B. Deau-Fischer, P. Franchi, M. Vignon, J. Zerbit, A. S. Cottereau, A. Touzart, P. Villarese, S. Kaltenbach, L. Lhermitte, V. Asnafi, D. Bouscary, L. Willems","doi":"10.1111/ejh.14325","DOIUrl":null,"url":null,"abstract":"Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%–2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%. With a 3.9-year median follow-up, 100% of patients with PTL had CR and none relapsed. On the contrary, 55% of DLBCL-T patients achieved CR among which only one was still in remission at the end of follow-up. Molecular parallels between PTL and Primary CNS Lymphoma (PCNSL) suggest shared origins, urging further research for tailored treatments and enhanced understanding of these lymphomas' biology.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"114 1","pages":"186-194"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14325","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14325","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%–2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%. With a 3.9-year median follow-up, 100% of patients with PTL had CR and none relapsed. On the contrary, 55% of DLBCL-T patients achieved CR among which only one was still in remission at the end of follow-up. Molecular parallels between PTL and Primary CNS Lymphoma (PCNSL) suggest shared origins, urging further research for tailored treatments and enhanced understanding of these lymphomas' biology.

Abstract Image

查看原文本刊更多论文

以R-CHOP加大剂量甲氨蝶呤作为一线疗法治疗睾丸受累大B细胞淋巴瘤患者的生物学发现和临床疗效

原发性睾丸淋巴瘤（PTL）是弥漫大B细胞淋巴瘤（DLBCL）的一种罕见病，占所有病例的1%-2%。结节性DLBCL累及睾丸（DLBCL-T）和PTL预后不良，中枢神经系统复发率高。15例PTL（5例）或DLBCL-T（10例）患者（中位年龄60岁）接受了大剂量甲氨蝶呤+R-CHOP治疗。总的来说，完全应答率（CR）为 73%，总体应答率为 86%。在3.9年的中位随访中，100%的PTL患者获得了CR，且无一复发。相反，55%的DLBCL-T患者获得了CR，其中只有一人在随访结束时仍处于缓解期。PTL和原发性中枢神经系统淋巴瘤（PCNSL）的分子相似性表明它们有着共同的起源，这促使人们进一步研究定制治疗方法，并加深对这些淋巴瘤生物学特性的了解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Haematology 医学-血液学

CiteScore

5.50

自引率

0.00%

发文量

168

审稿时长

4-8 weeks

期刊介绍： European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.